Ultrasound for Detecting Chemotherapy-Induced Peripheral Neuropathy
Trial Summary
Do I have to stop taking my current medications for this trial?
The protocol does not specify if you need to stop taking your current medications.
What data supports the idea that Ultrasound for Detecting Chemotherapy-Induced Peripheral Neuropathy is an effective treatment?
The available research shows that ultrasound is being explored as a tool to assess chemotherapy-induced peripheral neuropathy, but there is no direct evidence in the provided information that it is an effective treatment. Instead, ultrasound is used as a diagnostic method to evaluate nerve damage caused by chemotherapy. It helps in identifying and monitoring the condition, which can be crucial for managing symptoms and adjusting treatment plans. However, the research does not compare ultrasound to other treatments or provide specific data on its effectiveness as a treatment itself.12345
What safety data exists for using ultrasound to detect chemotherapy-induced peripheral neuropathy?
The research indicates that ultrasound has not been previously used specifically for assessing chemotherapy-induced peripheral neuropathy, particularly from oxaliplatin. However, ultrasound is an emerging technique in the study of peripheral nerve diseases. The safety data for oxaliplatin itself highlights that it causes peripheral neuropathy, which is a major adverse effect and dose-limiting toxicity. While ultrasound has been evaluated for taxane-induced neuropathy, specific safety data for its use in detecting oxaliplatin-induced neuropathy is not detailed in the provided research.24567
Is the drug Oxaliplatin a promising treatment for chemotherapy-induced peripheral neuropathy?
What is the purpose of this trial?
This pilot clinical trial studies how well ultrasound works in detecting oxaliplatin-induced neuropathy in patients with gastrointestinal cancer. Ultrasound may work better in diagnosing and detecting neuropathy in gastrointestinal cancer patients treated with the chemotherapy drug called a oxaliplatin.
Research Team
Roy E. Strowd
Principal Investigator
Wake Forest University Health Sciences
Eligibility Criteria
This trial is for patients with any stage of gastrointestinal or colorectal cancer who are currently or have previously been treated with oxaliplatin-based chemotherapy and now show signs of peripheral neuropathy. Participants must be able to understand and sign a consent form.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Ultrasound Assessment
Participants undergo peripheral nerve ultrasound to assess nerve cross-sectional area
Follow-up
Participants are monitored for changes in nerve conduction and neuropathy symptoms
Treatment Details
Interventions
- Oxaliplatin
- Ultrasound - Serial and Tibial Nerve
Oxaliplatin is already approved in European Union, United States, Canada, Japan, Switzerland, China for the following indications:
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
- Colorectal cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
National Cancer Institute (NCI)
Collaborator